Affimed (NASDAQ:AFMD) Receives Buy Rating from HC Wainwright

Affimed (NASDAQ:AFMD)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 173.97% from the stock’s previous close.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, September 9th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Affimed Trading Down 2.7 %

NASDAQ:AFMD opened at $3.65 on Friday. The stock’s 50-day simple moving average is $3.50 and its 200 day simple moving average is $4.54. Affimed has a 52-week low of $2.92 and a 52-week high of $8.95. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last issued its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. On average, analysts forecast that Affimed will post -4.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. Intellectus Partners LLC grew its position in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the period. Finally, Choreo LLC bought a new position in Affimed in the 2nd quarter worth $54,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.